Company Overview and News


Add CORI
to your dashboard

Headline News

Broadfin Capital, LLC - All Holdings - 13F 13D 13G Filings - Fintel.io

2018-01-03 fintel.io
Broadfin Capital, LLC has disclosed 45 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 676,005,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Broadfin Capital, LLC's top holdings are Heron Therapeutics, Inc. (NASDAQ:HRTX) , Corium International, Inc. (NASDAQ:CORI) , Retrophin, Inc. (NASDAQ:RTRX) , Horizon Pharma plc (NASDAQ:HZNP) , and Flamel Technologies S. (149-0)

Free Research Report as Corium's Revenue Grew 19.2%

2017-12-29 accesswire
LONDON, UK / ACCESSWIRE / December 29, 2017 / Active-Investors.com has just released a free earnings report on Corium International, Inc. (NASDAQ: CORI) (''Corium''). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CORI. The Company posted its financial results on November 16, 2017, for the fourth quarter of the fiscal year 2017. (8-0)

Biotech Analysis Central Pharma News: Agile CRL, Roche's Purchase, Mallinckrodt's Major Buy

2017-12-28 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (103-0)

Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look

2017-12-27 seekingalpha
For Agile Therapeutics (AGRX) shareholders, 2017 is ending pretty much the way it began. At the start of the year, AGRX saw a huge drop after the company announced results from its Phase 3 SECURE study. While the company noted in its press release that the top-line results were “positive,” the market was not convinced and the disappointment led to more than 80% drop in AGRX. Last week, AGRX suffered another setback as the FDA issued a CRL for AGRX’s Twirla. (24-0)

Biotech Forum Daily Digest: Behind Fate's Rally

2017-12-26 seekingalpha
Biotech ended the previous weak, a bit better than flat thanks to big upsurge in the small cap part of the sector on Friday. (317-2)

Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL

2017-12-26 seekingalpha
Today we will discuss Amgen’s (AMGN) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U.S. (651-2)

Biotech Forum Daily Digest: Synergy's CEO Leaves, Shareholders Cheer!

2017-12-22 seekingalpha
The biotech sector has a decent sized acquisition as 2017 comes to a close.  Roche is buying oncology concern Ignyta for a 75% premium.  M&A should see uptick in 2018. (408-1)

FDA declines to approve Agile's contraceptive patch - Channel NewsAsia

2017-12-22 channelnewsasia
REUTERS: Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company's contraceptive patch, citing deficiencies related to its adhesion test methods. (24-0)

FDA declines to approve Agile's contraceptive patch

2017-12-22 reuters
(Reuters) - Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company’s contraceptive patch, citing deficiencies related to its adhesion test methods. (24-0)

Integrated BioSci Research On Corium: A Stellar Investing Opportunity

2017-11-24 seekingalpha
The multi-billion dollars market for Alzheimer’s disease is lucrative. And, the company has a small market cap to warrant much further upsides. (90-0)

Corium International's (CORI) CEO Peter Staple on Q4 2017 Results - Earnings Call Transcript

2017-11-17 seekingalpha
Good day, ladies and gentlemen and welcome to Corium International's Conference Call for its Fourth Fiscal Quarter and Year-End 2017. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] And as a reminder, this conference call maybe recorded. (24-1)

BRIEF-Corium reports Q4 loss per share $0.36

2017-11-16 reuters
* Corium International Inc - ‍Cash and cash equivalents as of September 30, 2017 were $57.5 million​ Source text for Eikon: Further company coverage: (8-0)

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

Bioscience Catalysts: Global Blood Therapeutics And Vanda Pharmaceuticals

2017-10-31 seekingalpha
The bioscience catalyst series seeks to help readers making sense of the notable life science runners. (61-1)

CUSIP: 21887L107